AGENAgenus Inc.
Agenus Inc. (AGEN) sells immunotherapies and oncology-focused biologics, with a focus on T-cell engager (TCE) platforms and ADC (antibody-drug conjugate) candidates. The next catalyst is Dec 10, 2026 — Anticipated Dilutive Capital Raise / Secondary Offering, which will test the company’s ability to raise capital amid ongoing losses and a cash-burn trajectory.
- AGEN reported $124.18M in revenue for the 10-Q period ending June 30, 2026, but posted a net loss of $138.43M, with diluted EPS of -$0.01.
- Free cash flow (TTM) is -$209.53M, and net margin (TTM) is -111.5%, reflecting a highly leveraged business model.
- Debt-to-equity is negative at -0.05x, suggesting the company has more equity than debt, but shareholders’ equity is -$271.11M, indicating significant losses and a lack of capital structure stability.
The schedule
- Thu10Dec
Anticipated Dilutive Capital Raise / Secondary Offering The event will test market reaction to potential dilution of shares and its impact on valuation.
- Thu31Dec
- Thu1Apr
- Thu1Jul
- Thu9Sep
Agenus to Participate in Upcoming September Investor ... The event will test investor interest and market reaction to the company's participation in investor events.
- Tue14Sep
Agenus to Participate in Upcoming September Investor ... The event will test the market's response to follow-up investor interactions and any new information shared.
- Thu30Sep
Past
- Mon13Jul
Actual outcome: Bull · $7.43 at outcome
AGEN's stock surged following a positive clinical trial readout, indicating strong efficacy and safety data for its lead therapy. The results exceeded expectations and signaled potential regulatory approval, driving investor confidence and valuation re-rating. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-12: +162.5% from 2026-06-24 (~2.2σ). Target date 2026-08-07 reached; move through 2026-10-12 observed.
AGEN's stock surged following a positive clinical trial readout, indicating strong efficacy and safety data for its lead therapy. The results exceeded expectations and signaled potential regulatory approval, driving investor confidence and valuation re-rating. [Market retrospective · Long-Term (31–75 days)] Updated observation 2026-10-12: +162.5% from 2026-06-24 (~2.2σ). Target date 2026-08-07 reached; move through 2026-10-12 observed.
